When was Lexicon Pharmaceuticals founded?

Lexicon Pharmaceuticals was founded in 1995 and raised its 1st funding round 3 years after it was founded.

Where is Lexicon Pharmaceuticals located?

Lexicon Pharmaceuticals is headquartered in The Woodlands, United States.

How many employees does Lexicon Pharmaceuticals have?

As of May 31, 2026, the latest employee count at Lexicon Pharmaceuticals is 284.

Is Lexicon Pharmaceuticals a funded company?

Lexicon Pharmaceuticals is a funded company, having raised an undisclosed amount across 11 funding rounds to date. The company's 1st funding round was a $***** Unattributed round, raised on May 1998.

When was the latest funding round of Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals' latest funding was a $***** Post IPO round on Feb 02, 2026, with participation from 0 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $1.17B in funding in 2026 to date.

What is the annual revenue of Lexicon Pharmaceuticals?

Annual revenue of Lexicon Pharmaceuticals is between $10M and $50M as on Dec 31, 2025

Where does Lexicon Pharmaceuticals rank among its competitors?

Lexicon Pharmaceuticals ranks 10th amongst 338 active competitors, of which 122 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Lexicon Pharmaceuticals, which secured $55.7M in Feb, 2026.

Who are the top competitors of Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals' top competitors include Sana Biotechnology, Seer and Tango Therapeutics. Among them, Lexicon Pharmaceuticals secured the most recent funding round in February, 2026.

Lexicon Pharmaceuticals - 2026 Company Profile, Funding, Competitors & Financials

Lexicon Pharmaceuticals is a public company based in The Woodlands (United States), founded in 1995. It operates as a Developer of small molecule drugs for diffrent health diseases. Lexicon Pharmaceuticals has raised an undisclosed amount in funding. The company has 338 active competitors, including 122 funded and 67 that have exited. Its top competitors include companies like Sana Biotechnology, Seer and Tango Therapeutics.

Company Details

Developer of small molecule drugs for diffrent health diseases. It uses gene trapping and gene targeting technologies to discover new drug targets and develop small molecule drugs across therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.

Website: lexpharma.com
Social

Key Metrics

Founded Year

1995

Location

The Woodlands, United States

Stage

Public

Latest Funding Round

Post IPO, Feb 02, 2026, $*****

Investors

New Enterprise Associates & 4 more

Ranked

10^th among 338 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2025

Employee Count

284 as on May 31, 2026

Similar Companies

Sana Biotechnology & 425 more

Exit Details

Public

View Lexicon Pharmaceuticals' full profile

Lexicon Pharmaceuticals is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
LEXICON PHARMACEUTICALS, INC. CIN: 5028487 , United States, Active	Oct 26, 2016	-	-	-
LEXICON PHARMACEUTICALS, INC./DE CIN: 1062822 , United States, Active		$1M - $10M (As on Dec 31, 2013)	-	-
, LEXICON PHARMACEUTICALS, INC. CIN: 76-0474169 , United States, Active	Apr 06, 2000	-	-	-
LEXICON PHARMACEUTICALS, INC. CIN: 1062822 , United States, Active	Jul 06, 1995	$10M - $50M (As on Dec 31, 2025)	83 (As on Dec 31, 2021)	-

Lexicon Pharmaceuticals got listed on Apr 07, 2000.

Click here to take a look at Lexicon Pharmaceuticals's IPO in detail

Lexicon Pharmaceuticals has raised funding over 11 rounds. Its first funding round was on May 1998. Lexicon Pharmaceuticals has 5 institutional investors.

Here is the list of recent funding rounds of Lexicon Pharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 02, 2026	9808578	Post IPO	5754331	2019240	8712500	7370741
Aug 03, 2022	9666846	Post IPO	1132942	2857770	7745158	6379850
Mar 24, 2017	3252213	Post IPO	8825091	8983449	7133529	8409238

Access funding benchmarks and valuations. Sign up today!

View details of Lexicon Pharmaceuticals's funding rounds and investors

Lexicon Pharmaceuticals' employee count trend

Lexicon Pharmaceuticals has 284 employees as of May 26. Here is Lexicon Pharmaceuticals's employee count trend over the years:

Employee count trend for Lexicon Pharmaceuticals

Uncover Lexicon Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Lexicon Pharmaceuticals include Sana Biotechnology, Seer and Tango Therapeutics. Here is the list of Top 10 competitors of Lexicon Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 17 others	75/100
2nd	Seer 2017, San Francisco (United States), Public	Developer of proteomics platform for early detection of cancer and neurological diseases	$128M	aMoon, Fidelity Investments & 15 others	72/100
3rd	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	71/100
4th	Adocia 2005, Lyon (France), Public	Developer of therapeutics for the treatment of diabetes and obesity	$26M	Stifel, Smalt Capital & 6 others	69/100
5th	Maze Therapeutics 2018, Redwood City (United States), Public	Developer of genetic bio-markers in neurological, metabolic, and renal diseases	$496M	Deep Track Capital, City Hill Ventures & 21 others	66/100
6th	Metabolon 2000, Morrisville (United States), Series H	Provider of solutions for biomarker discovery, diagnostic tests and personalized medicine	$166M	Sevin Rosen, Syngenta Group Ventures & 17 others	66/100
7th	Kailera 2024, Waltham (United States), Public	Developer of therapies for treating obesity and related conditions	$1B	RTW Investments, Bain Capital Life Sciences ... & 12 others	65/100
8th	Cellino 2017, Cambridge (United States), Series A	Developer of autologous cell therapies	$125M	Khosla Ventures, Humboldt Fund & 7 others	65/100
9th	Quell 2019, London (United Kingdom), Series B	Developer of engineered regulatory T cell therapies for immune diseases	$344M	Syncona, Fidelity Investments & 17 others	64/100
10th	Lexicon Pharmaceuticals 1995, The Woodlands (United States), Public	Developer of small molecule drugs for diffrent health diseases	-	New Enterprise Associates, Bay City Capital ... & 3 others	64/100